Navigation Links
Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
Date:9/6/2007

KNOXVILLE, TN--Provectus Pharmaceuticals, Inc. (OTCBB:PVCT) announced that it has obtained approval to begin Phase 2 clinical testing of Provecta for the treatment of Stage III and IV metastatic melanoma, the most aggressive and deadly form of skin cancer. The multi-center study is designed to evaluate efficacy of Provecta in a total of 80 subjects.

In the study, Provecta will be injected into up to 20 tumors in each subject. Additional treatment with Provecta may be made 8 to 16 weeks after this initial injection, if deemed necessary by the investigator. Response will be observed for 1 year, during which data will be gathered for assessment of objective response rate, progression free survival, quality of life and safety. In addition, CT imaging will be used to monitor changes in any internal (e.g., visceral or brain) metastases. The lead site for the study is the Sydney Melanoma Unit in Australia. Over the next several months the study will expand to include sites in a number of major population centers in Australia as well as several sites in the U.S.

Craig Dees, Ph.D., Chief Executive Officer of Provectus, stated, Building on the results from our Phase 1 study, which looked at safety and objective response upon injection of Provecta into more than 100 metastatic melanoma tumors in 20 subjects, we have put forth an aggressive clinical plan to drive toward approval of the drug for use in this devastating disease. Dees continued, Preliminary analysis of data from Phase 1 shows that Provecta, which has received orphan drug designation in the U.S., was well tolerated with generally mild side effects. Having completed final follow-up for the last of these subjects, we expect to announce summary response data in the near future.


'/>"/>
Contact: Janet Vasquez
janet@investorrelationsgroup.com
212-825-3210
Provectus Pharmaceuticals
Source:Eurekalert

Page: 1

Related medicine news :

1. Risk of heart disease begins in teens
2. Cancer Begins With Epigenetic Changes: Study
3. Learning About Healthy Diet Choices Begins At Schools
4. China Begins Human Trials For HIV/AIDS Drug
5. Administration of Fish Drug for Asthma Patients Begins in Andhra
6. Harvard Begins Controversial Human Stem Cell Cloning Project
7. Writing on the Wall - Lead Poisoning Begins at Home?Paints Could Be Toxic!
8. The Blessing of Good Mental Health Begins with Breast Milk, Says a Study
9. India sounds bird flu alert as migration season begins
10. Keys to Good Health in Old Age Begins in Midlife
11. Cancer Prevention Begins During Pregnancy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... (PRWEB) January 23, 2015 VogueQueen is a ... affordable prices and many designers are thrilled to have it ... business announces its new collection of prom dresses for the ... to drive the strategic vision and he focuses on continuing ...
(Date:1/22/2015)... York, New York (PRWEB) January 22, 2015 ... http://www.vaginalmeshlawsuit2015.com/ ) in the U.S. District Court, Southern District of ... C.R. Bard, Inc. in that proceeding’s first bellwether trial. In ... request for a new trial after finding that C.R. Bard ...
(Date:1/22/2015)... 2015 For over 20 years, Dr. David Cruz ... Vista area has treated just about every type of injury ... And for those same twenty-plus years, the team at ... injuries with the best possible doctor. With the combined ...
(Date:1/22/2015)... 2015 Recently, Weddingshe.com has added many trendy ... announced its highest annual revenues in the past three years. ... glamorous wedding dresses. , According to the sales manager of ... promotions for them in 2015. This point can be reflected ...
(Date:1/22/2015)... 2015 As interest in the value of ... momentum worldwide, Rev. Eric J. Hall , president and ... (HCCN), will be the keynote speaker on January 27 at ... health system. , The conference, “Hope and Resilience: Innovative and ...
Breaking Medicine News(10 mins):Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3
... ... leading direct-to-consumer provider of premium dietary supplements, announces the release of their new ... ... Products®, a leading direct-to-consumer provider of premium dietary supplements, announces the release of ...
... ... HiveMind Marketing, Inc. ( www.hivemindinc.com ), a new marketing “mashup” ... and social media marketing, announced today that the firm has been ... a leader in high-performance BioAnalytical instruments, software, and assays for basic ...
... ... a longer life. But it,s only worth it if people remain mentally and physically healthy. ... ... -- Armelle Productions announces the launch of iStayYoung™ to help everyone stay young, no matter ...
... , ... Invited To Enjoy World-Class Jazz At CareFusion Newport Jazz Festival, , ... Newport, R.I. (PRWEB) June 14, 2010 ... health care professionals who would like to attend the 2010 CareFusion Newport Jazz Festival ...
... conducted by researchers in The Netherlands confirmed that children ... of remission than those with remote symptomatic epilepsy. Results ... Epilepsia , a journal published by Wiley-Blackwell on behalf ... the Epilepsy Foundation, a person is considered to have ...
... ... States will be working in the fields. Although the United States was one of the ... allow children to work long hours in hazardous jobs. , ... Washington, D.C.(Vocus) June 11, 2010 -- Today on World Day ...
Cached Medicine News:Health News:Purity Products Releases Ultimate Sleep Plus Melatonin 2Health News:Molecular Devices Relaunches with HiveMind Marketing 2Health News:Molecular Devices Relaunches with HiveMind Marketing 3Health News:Molecular Devices Relaunches with HiveMind Marketing 4Health News:iStayYoung Launches – Live Longer, and Better. Free for Seniors 65+ 2Health News:iStayYoung Launches – Live Longer, and Better. Free for Seniors 65+ 3Health News:CareFusion Newport Jazz Festival Discounts Tickets for Health Care Practitioners 2Health News:Study confirms favorable long-term prognosis of epilepsy 2Health News:AFOP's Children in the Fields Campaign Raises Awareness of Child Labor in the U.S. 2Health News:AFOP's Children in the Fields Campaign Raises Awareness of Child Labor in the U.S. 3
(Date:1/23/2015)... MONMOUTH JUNCTION, N.J. , Jan. 23, 2015 ... immunotherapy company commercializing its CytoSorb® extracorporeal cytokine adsorber ... surgery patients, announced the receipt of $385,642, net ... approved participant of the Technology Business Tax Certificate ...
(Date:1/23/2015)... and BOSTON , January 23, ... drug discovery and development company, is delighted to announce that ... been awarded to Miles Congreve (Vice President of ... and Malcolm Weir (Chief Executive Officer and co-founder) ...
(Date:1/22/2015)... BOULDER, Colo. , Jan. 22, 2015  BiOptix is ... Klakamp as Vice President of Chemistry and Biochemistry. Scott ... Takeda Pharmaceuticals, AstraZeneca Pharmaceuticals, and Amgen throughout the course ... and development. "Scott is a nationally recognized ...
Breaking Medicine Technology:CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2
... Aug. 16, 2011 Practice Fusion,s Research Division ... the 20 most commonly prescribed medications by specialty ... (EMR) system. Topping the list are prescriptions for ... (Simvastatin, Internal Medicine ), infection (Amoxicillin, ...
... Edwards, Inc. (Nasdaq: MSHL ), an oncology ... targeting cancer metabolism, announced today that its Investigational New ... lead NADH oxidase inhibitor, has been approved by the ... to initiate a Phase I clinical trial of intravenous ...
Cached Medicine Technology:2011 Prescription Index from the Practice Fusion Research Division 22011 Prescription Index from the Practice Fusion Research Division 32011 Prescription Index from the Practice Fusion Research Division 4Marshall Edwards Announces FDA Approval of Investigational New Drug Application for Lead Candidate ME-143 2Marshall Edwards Announces FDA Approval of Investigational New Drug Application for Lead Candidate ME-143 3
... semi-automated agarose gel electrophoresis system is ... steps involved in classic electrophoresis and ... out all phases of electrophoresis ... incubation to staining, destaining and drying. ...
Handheld Digital Retinal Camera...
Inquire...
Millennium Forceps designed specifically for graft insertion....
Medicine Products: